Strategic Acquisition Fuels Personalized healthcare Vision

The Invitz Ecosystem is poised to considerably expand its digital healthcare capabilities with the impending acquisition of a for-profit general hospital in Guam, USA. This strategic move, slated for completion in the latter half of this year, represents a crucial step in realizing Invitz’s “Herb and Spoke” model for healthcare delivery, integrating advanced digital platforms with physical medical facilities.

Shin Kyu-kyu, Chairman of Invitz Ecosystem, recently unveiled the company’s ambitious blueprint for a complete digital healthcare platform. According to Chairman Shin, the Guam-based hospital will serve as a vital testing ground for all of Invitz’s proprietary digital technologies, paving the way for personalized medicine on a global scale.

Guam Hospital: A Hub for Digital Healthcare Innovation

Invitz Ecosystem plans to invest approximately ₩100 billion to acquire 100% ownership of Guam’s ‘Regional Medical City,’ the largest general hospital on the island. Boasting around 125 beds and generating annual sales of ₩300 billion, the hospital caters to a diverse patient base, including Guam residents, US military personnel, and Korean tourists. Following the acquisition, Invitz intends to rapidly integrate its cutting-edge digital infrastructure into the hospital’s operations.

This acquisition builds upon Invitz Ecosystem’s previous investments in healthcare,including participation in the US hospital’s investment process in 2012 and the acquisition of Sun Hospital in 2017.

The “Herb and Spoke” Model: A Personalized Approach

The Guam hospital acquisition represents the final piece of Invitz’s healthcare business strategy. The core of this strategy lies in a digital platform that analyzes patient genomes to deliver personalized healthcare solutions. This platform will connect the Guam-based hospital (the “hub”) with local healthcare providers (the “spokes”), creating a seamless network of care. The “Herb and Spoke” model, borrowed from logistics, signifies the centralized collection of patient data and its distribution to various specialists for tailored treatment plans.

The US hospital will be a test bed to test all the digital platforms owned by the company.
Shin Kyu-kyu,Chairman of Invitz Ecosystem

Invitz Ecosystem: A Leader in Genomic analysis and AI-Driven Healthcare

Chairman Shin leads the Invitz Ecosystem,a conglomerate comprising five bio and healthcare affiliates,including CG Inbates. With a background in the Ministry of Foreign Affairs and Trade Bargaining Headquarters, Chairman Shin has steered Invitz towards becoming a frontrunner in genome analysis and artificial intelligence (AI)-driven healthcare.

Invitz Genomics has spearheaded initiatives such as building a database of 50,000 Korean genomes, including 10,000 from Jeju residents. The company was also selected for the K-DNA project, a national bio big data construction pilot program with a government investment of ₩6066 billion over five years.

AI-Powered disease Prediction and Personalized Mobile Healthcare

Invitz’s AI disease prediction system (IRS) can currently diagnose 32 diseases, including 11 types of cancer, with an accuracy rate exceeding 80%. The company plans to launch a mobile request in August, providing patients with access to comprehensive healthcare facts and diagnostic tools directly on their smartphones.

Chairman Shin envisions a future where the patient will hold a general hospital with 32 medical care in his hand. Invitz is also developing other platforms,such as the Healthcare Monitoring Platform (ICHMS),to further enhance patient care and monitoring.

Advancing Cancer Treatment with mRNA Vaccines and AI

The Invitz ecosystem is actively engaged in new drug development, including mRNA-based anticancer vaccines.CG Invates is set to present its latest findings at the American Society of Clinical Oncology (ASCO) meeting in Chicago this month. The company has developed an AI-designed colorectal cancer treatment that demonstrates significantly improved protein expression and anticancer immunity activity compared to existing therapies.

The potential of mRNA vaccines in cancer treatment is meaningful. While still in development, these vaccines aim to stimulate the patient’s immune system to recognize and attack cancer cells. Companies like moderna and BioNTech are also heavily invested in this field, showcasing the growing interest and potential of mRNA technology in oncology.